EA201891752A2 - Фармацевтическая композиция для улучшения состояния при хронической почечной недостаточности или предотвращения ее прогрессирования - Google Patents

Фармацевтическая композиция для улучшения состояния при хронической почечной недостаточности или предотвращения ее прогрессирования

Info

Publication number
EA201891752A2
EA201891752A2 EA201891752A EA201891752A EA201891752A2 EA 201891752 A2 EA201891752 A2 EA 201891752A2 EA 201891752 A EA201891752 A EA 201891752A EA 201891752 A EA201891752 A EA 201891752A EA 201891752 A2 EA201891752 A2 EA 201891752A2
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
chronic renal
progression
prevent
condition during
Prior art date
Application number
EA201891752A
Other languages
English (en)
Other versions
EA201891752A3 (ru
EA035709B1 (ru
Inventor
Анкит Шиам Сингх
Ведпракаш Мишра
Неелима Тонгра
Original Assignee
Фримлайн Прайвет Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фримлайн Прайвет Лимитед filed Critical Фримлайн Прайвет Лимитед
Publication of EA201891752A2 publication Critical patent/EA201891752A2/ru
Publication of EA201891752A3 publication Critical patent/EA201891752A3/ru
Publication of EA035709B1 publication Critical patent/EA035709B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящая заявка относится к фармацевтической композиции/составу для улучшения состояния при хронической почечной недостаточности (ХПН), вызванной воспалением и/или недостаточной экспрессией клото, или предотвращения ее развития. Более конкретно, настоящее изобретение относится к композиции/составу, содержащему синергическую комбинацию пальмитоилэтаноламида (ПЭА), холекальциферола и одного или нескольких природных ингредиентов. Настоящее изобретение также обеспечивает различные составы и способы их получения.
EA201891752A 2017-09-05 2018-08-31 Фармацевтическая композиция для улучшения состояния при хронической почечной недостаточности или предотвращения ее прогрессирования EA035709B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201721031443 2017-09-05

Publications (3)

Publication Number Publication Date
EA201891752A2 true EA201891752A2 (ru) 2019-03-29
EA201891752A3 EA201891752A3 (ru) 2019-05-31
EA035709B1 EA035709B1 (ru) 2020-07-29

Family

ID=63490286

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891752A EA035709B1 (ru) 2017-09-05 2018-08-31 Фармацевтическая композиция для улучшения состояния при хронической почечной недостаточности или предотвращения ее прогрессирования

Country Status (8)

Country Link
US (1) US10973782B2 (ru)
EP (1) EP3449943B1 (ru)
CA (1) CA3015399C (ru)
EA (1) EA035709B1 (ru)
MY (1) MY186286A (ru)
PH (1) PH12018000227B1 (ru)
SG (1) SG10201807034XA (ru)
UA (1) UA123448C2 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019241702A1 (en) * 2018-06-14 2019-12-19 The Texas A&M University System Anti-inflammatory formulations and uses thereof including a combination of palmitoylethanolamide and plant-based polyphenols
CA3123524C (en) * 2019-01-02 2024-01-23 Celagenex Research (India) Pvt. Ltd. Synergistic nutritional compositions for pain management

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506224A (en) 1991-12-31 1996-04-09 Lifegroup S.P.A. N-acyl derivatives of aminoalcohols active as local autacoids and useful in the therapy of autoimmune processes
IT1271266B (it) 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
DE69942317D1 (de) 1998-05-29 2010-06-10 Neurosciences Res Found Schmerzlinderung mit anandamide
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
MXPA03008823A (es) 2001-03-27 2004-08-12 Univ California Metodos, compuestos y composiciones para reducir la grasa corporal y modular el metabolismo de los acidos grasos.
CA2542547A1 (en) 2003-10-16 2005-05-26 Daniele Piomelli Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism
ITPD20050224A1 (it) * 2005-07-19 2007-01-20 Actimex Srl Composizioni contenenti micronutrienti aventi in particolare attivita' antiossidante e loro impiego
US20070207225A1 (en) * 2006-03-03 2007-09-06 Francesco Squadrito Genistein modulated reduction of cardiovascular risk factors
EP1844784B1 (en) 2006-03-28 2010-04-21 Epitech Group S.r.l. A pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system
US8680053B2 (en) * 2008-07-09 2014-03-25 Quercegen Pharmaceuticals Llc Improving renal function with quercetin-containing compositions
PT2334202E (pt) * 2008-09-04 2012-02-28 Cargill Inc Fabrico de comprimidos de eritritol
CN102186459A (zh) 2009-09-07 2011-09-14 晶源集团股份责任有限公司 含有超微粒化十六酰胺乙醇的组合物
CA2780165A1 (en) * 2009-10-20 2011-04-28 Herbonis Ag Use of extracts from salonum glaucophyllum for treating bone metabolism disorders and kidney disorders
CA2843265C (en) 2010-07-28 2019-09-17 The Regents Of The University Of California Peripherally restricted faah inhibitors
ES2648051T3 (es) * 2010-10-04 2017-12-28 Epitech Group S.P.A. Uso de amidas de ácidos mono y dicarboxílicos en el tratamiento de enfermedades renales
EP2744778B1 (en) 2011-08-19 2019-01-16 The Regents of The University of California Meta-substituted biphenyl peripherally restricted faah inhibitors
US20130085121A1 (en) * 2011-09-30 2013-04-04 Jianguo Wang Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d
JP5982016B2 (ja) * 2012-02-17 2016-08-31 エピテック グループ エッセ．エッレ．エッレ． 炎症性疾患の治療に使用されるｎ−アシルエタノールアミンに対して特異的なアミダーゼを調節する組成物及び方法
WO2014004676A1 (en) * 2012-06-26 2014-01-03 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors as neuroprotective agents in the cns
RU2685425C2 (ru) 2012-07-24 2019-04-18 Биал-Портела Энд Ка, С.А. Соединения мочевины и их применение в качестве ингибиторов ферментов
NL2011448C2 (en) 2012-09-17 2015-01-29 Jp Russell Science Holding Ltd Pharmaceutical or neutraceutical composition comprising palmitoylethanolamide particles.
JP2016523245A (ja) * 2013-06-21 2016-08-08 ノークス、デイビッド Ｄｅ−ｖｄｂｐ及び不飽和脂肪酸とのビタミンｄ複合体、並びに治療法におけるその使用
ITMI20131180A1 (it) 2013-07-15 2015-01-16 Fond Istituto Italiano Di Tecnologia O-alchil triazolil carbammati come inibitori di idrolasi delle ammidi degli acidi grassi (faah)
US9828352B2 (en) 2013-07-18 2017-11-28 Fondazione Istituto Italiano Di Tecnologia Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR)
SI3024825T1 (sl) 2013-07-24 2017-11-30 Bial - Portela & Ca, S.A. Imidazolkarboksamidi in njihova uporaba kot faah inhibitorji
MX2016001391A (es) 2013-08-01 2016-08-17 BIAL - PORTELA & Cª S A Compuestos de urea y su uso como inhibidores de la enzima amida hidrolasa de acido graso (faah).
EP2921167B1 (en) * 2014-03-19 2016-08-17 EPITECH GROUP S.p.A. Pharmaceutical composition comprising palmitoylethanolamide and l-acetylcarnitine
WO2015157313A1 (en) 2014-04-07 2015-10-15 The Regents Of The University Of California Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments
PL2944309T3 (pl) 2014-05-14 2019-09-30 Epitech Group S.P.A. Zastosowanie palmitoiloetanoloamidu w połączeniu z opioidami
EA038593B1 (ru) 2014-10-22 2021-09-21 Эген Лайф Италия Срл Состав, содержащий спирулину и пальмитоилэтаноламид и/или их фармацевтически приемлемые соли, и его применение в профилактике и лечении состояний гиперактивированных тканей
NL2014464B1 (en) 2015-03-16 2017-01-13 Vanderbilt Science Holding Ltd Composition for use in the treatment of neuropathic pain.
WO2016183134A1 (en) 2015-05-12 2016-11-17 Cutting Edge Medical Solutions, Llc Palmitoylethanolamide compositions
MA42130A (fr) 2015-05-21 2018-03-28 Therapix Biosciences Ltd Combinaisons d'opioïdes et de n-acyléthanolamines
MA47844A (fr) 2015-06-04 2021-05-05 Ali Res Srls Combinaison comprenant du palmitoyléthanolamide (pea) et du e lycopène pour utilisation dans le traitement de maladies inflammatoires
ITUB20153066A1 (it) * 2015-08-11 2017-02-11 Graal S R L Composizione alimentare e/o nutraceutica contenente pea

Also Published As

Publication number Publication date
PH12018000227A1 (en) 2019-03-11
UA123448C2 (uk) 2021-04-07
EA201891752A3 (ru) 2019-05-31
US10973782B2 (en) 2021-04-13
EP3449943A1 (en) 2019-03-06
US20190070133A1 (en) 2019-03-07
MY186286A (en) 2021-07-05
BR102018067846A2 (pt) 2020-07-07
PH12018000227B1 (en) 2019-03-11
CA3015399C (en) 2020-03-24
EP3449943B1 (en) 2022-08-31
EA035709B1 (ru) 2020-07-29
SG10201807034XA (en) 2019-04-29
CA3015399A1 (en) 2019-03-05

Similar Documents

Publication Publication Date Title
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
BR112017016636A2 (pt) formulação líquida estável para anticorpos monoclonais
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
MX2022003757A (es) Composiciones para el cuidado bucal con actividad anticaries.
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
BR112015015870A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
AR104835A1 (es) Composiciones nutricionales que contienen un nivel elevado de inositol y uso de las mismas
BR112019018088A2 (pt) Composições propositadamente selecionadas que compreendem canabinoides purificados e/ou terpenos purificados
CO2021014260A2 (es) Formas sólidas de un inhibidor de glyt1
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
MX388970B (es) Formulaciones para estabilizar la humedad en alimentos musculares.
PE20160010A1 (es) Composicion nutricional de la anti regurgitacion
BR112017016497A2 (pt) composições e métodos para metabolismo muscular melhorado
EA202090732A1 (ru) Составы для трансдермального введения
EA201891752A2 (ru) Фармацевтическая композиция для улучшения состояния при хронической почечной недостаточности или предотвращения ее прогрессирования
EA202090971A1 (ru) Способы применения и композиции, содержащие дулаглутид
BR112015023368A2 (pt) método de tratamento de deficiência de vitamina b12
MX2024014771A (es) Terapia combinada
EA201890477A1 (ru) Инкапсулированная композиция финголимода